24-Mar-2017 IP Watch
Some of the main TRIPS-plus measures historically pushed for by countries such as the United States or the EU are being again proposed at the EU-Mercosur FTA.
Switzerland is pushing for tighter patent protection, data exclusivity and dropping compulsory licencing under a new free trade agreement.
In this note, Switzerland is proposing that India agree to broader patentable subject matter, particularly as regards biologic products.
MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’
7-Mar-2017 People Over Profit
People Over Profit Statement on the 17th Round of Negotiations of the Regional Comprehensive Economic Partnership (RCEP) in Kobe, Japan 27 Feb-3 March 2017
Médecins Sans Frontières (MSF) raises concerns over provisions under negotiation in the RCEP investment chapter that threaten to restrict access to affordable medicines for millions of people
28-Feb-2017 Japan Times
The RCEP Kobe conference is the first round of negotiations this year and the first since U.S. President Donald Trump announced he was canceling America’s participation in the Trans-Pacific Partnership. The Kobe meeting will set the tone for the remaining negotiations this year, however NGO representatives, noted that the TPP would be the elephant in the room.
28-Feb-2017 The Wire
Concerns remain over the impact of RCEP negotiations on public health and access to medicines.
27-Feb-2017 Sunday Guardian Live
There is no principled basis for EU’s demand of extending patent protection beyond the period of 20 years.
The intellectual property provisions initiated by Japan and South Korea go far beyond the requirements needed under international trade rules.
10-Feb-2017 The Hindu
The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements
El día 21 tendrán lugar decenas de manifestaciones en varios países europeos contra el acuerdo comercial con Canadá. 3,5 millones de personas entregaron sus firmas para detener este tratado y el TTIP.
10-Jan-2017 Financial Express
The pace of implementation of Indo-Japan free trade agreement needs to be further enhanced in order to exploit the huge potential of the pact, Commerce and Industry Minister Nirmala Sitharaman said.
2-Jan-2017 IA Reporter
Investigation: As Colombia pushes for cancer drug price-cut and considers compulsory licensing, Novartis responds with quiet filing of an investment treaty notice
Novartis lodged a formal notice of dispute under the Switzerland-Colombia BIT.
Global pharmaceutical companies have successfully lobbied for longer monopolies in trade agreements which have delayed the availability of cheaper medicines, resulting in higher prices.
Longer monopolies and single legal proceedings vs. generics - the gift of CETA to Canadian drug patentees
Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada–European Union trade agreement
12-Dec-2016 The Times of India
Doctors Without Borders/Medecins Sans Frontieres (MSF) and other health groups have reiterated concerns about harmful intellectual property provisions in the RCEP
7-Dec-2016 IP Watch
Threats to affordable access to medicines continue unabated
6-Dec-2016 The Jakarta Post
As trade negotiators from 16 countries gather in Indonesia to deliberate the terms of trade agreement — the Regional Comprehensive Economic Partnership agreement (RCEP), access to low-cost generic medicines is under grave threat.
5-Dec-2016 Médecins Sans Frontières
MSF press release: RCEP trade deal negotiators must reject terms that would harm access to medicines
International medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines.